Jazz, AbCellera Partner to Develop Multispecific T-Cell Engagers for Gastrointestinal Cancers and Solid Tumors

Jazz Pharmaceuticals and AbCellera have announced a preclinical research collaboration, option, and license agreement focused on the discovery and development of multispecific T-cell engaging antibodies for gastrointestinal (GI) cancers and other solid tumors. Under the agreement, Jazz will have the exclusive option to develop and commercialize therapeutic antibodies generated through the collaboration, while AbCellera will conduct discovery and early-stage research activities.¹

The agreement includes $56 million in upfront payments to AbCellera for the first two research programs, with an additional $28 million payable upon initiation of a third program. If Jazz exercises its development options, AbCellera could receive up to $792 million per program in option fees and development, regulatory, and commercial milestone payments, as well as tiered royalties on future sales.¹

Could multispecific T-cell engagers improve outcomes in difficult-to-treat solid tumors?

T-cell engagers are designed to redirect immune cells toward cancer cells by linking T cells to tumor-associated antigens. The therapeutic approach has generated significant clinical success in certain hematologic malignancies, leading researchers to explore whether similar strategies can be applied to solid tumors.²

However, solid tumors present unique challenges. Tumor heterogeneity, limited immune-cell infiltration, and immunosuppressive tumor microenvironments can reduce the effectiveness of immune-based therapies. Researchers have increasingly investigated multispecific antibody designs that may improve tumor targeting and enhance immune activation while minimizing off-target effects.²

The Jazz and AbCellera collaboration will initially focus on multiple GI cancers and other solid tumors, areas where unmet medical need remains significant despite advances in immunotherapy and targeted treatment approaches.¹

What advantages could AbCellera's T-cell engager platform bring to the collaboration?

According to the companies, the partnership will leverage AbCellera's integrated T-cell engager platform, which includes proprietary CD3-binding antibodies, costimulatory targeting components, multispecific protein engineering technologies, and high-throughput functional screening assays.¹

The platform is designed to support the identification and optimization of antibody candidates that can effectively engage T cells while maintaining favorable drug development characteristics. AbCellera's capabilities also extend from antibody discovery through clinical manufacturing, providing a framework for advancing candidates from early research into later-stage development.¹

Under the terms of the agreement, AbCellera will conduct discovery activities for two initial programs and has committed to initiating a third program within 12 months. Jazz will retain the option to advance each resulting program into clinical development.¹

Why are developers pursuing multispecific antibody approaches in oncology?

Interest in multispecific antibodies has grown as researchers seek therapies capable of interacting with multiple biological targets simultaneously. Unlike conventional monoclonal antibodies, multispecific formats can be engineered to perform several functions at once, including recruiting immune cells, enhancing tumor selectivity, and activating complementary immune pathways.³

In oncology, these approaches may help address mechanisms that allow tumors to evade immune surveillance. By targeting multiple pathways or cellular interactions simultaneously, multispecific antibodies could potentially improve antitumor activity compared with therapies directed at a single target.³

Several companies have expanded investments in T-cell engager technologies in recent years as evidence continues to emerge supporting their potential role in cancer treatment beyond blood cancers.²

What could this partnership mean for gastrointestinal cancer research?

GI cancers remain a major contributor to global cancer incidence and mortality. Despite advances in screening, surgery, targeted therapies, and immunotherapy, outcomes remain poor for many patients with advanced disease.⁴

The collaboration expands Jazz's oncology research efforts in GI cancers while providing AbCellera an opportunity to apply its antibody discovery platform to a new set of therapeutic programs. Although the partnership remains in the preclinical stage, it reflects continued industry interest in developing next-generation immune-engaging therapies capable of addressing unmet needs in solid tumors.

Future progress will depend on whether the resulting multispecific T-cell engagers can demonstrate sufficient efficacy and safety as they advance through preclinical and clinical development. Success could contribute to broader efforts to extend the benefits of T-cell engager therapies to patients with GI cancers and other solid tumors.

References

1. Jazz Pharmaceuticals and AbCellera announce collaboration to discover next-generation T-cell engaging multispecific antibodies. (2026 Jun 17). PR Newswire. https://prnmedia.prnewswire.com/news-releases/jazz-pharmaceuticals-and-abcellera-announce-collaboration-to-discover-next-generation-t-cell-engaging-multispecific-antibodies-302802284.html
2. Goebeler ME, Bargou RC. (2020 Jul). T cell-engaging therapies, BiTEs and beyond. Nat Rev Clin Oncol. https://pubmed.ncbi.nlm.nih.gov/32242094/
3. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. (2019 Aug). Bispecific antibodies, a mechanistic review of the pipeline. Nat Rev Drug Discov. https://pubmed.ncbi.nlm.nih.gov/31175342/
4. World Health Organization. Cancer fact sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer